Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa

This study has been completed.
Danone Research
Information provided by (Responsible Party):
Rene Rizzoli, University Hospital, Geneva Identifier:
First received: March 29, 2013
Last updated: April 2, 2013
Last verified: March 2013
This multicentre, randomised, double-blind, 2-parallel group, controlled trial aims to investigate whether oral milk protein supplements led to increase in serum Insulin-like Growth Factor-I levels (IGF-I) as compared with a control group fed with an iso-caloric supplement, in women with anorexia nervosa. Subjects receive either 150g/day of tested product or control product for 4-week, followed by a 4-week follow-up.

Condition Intervention Phase
Anorexia Nervosa
Dietary Supplement: Oral protein supplement (Tested product)
Dietary Supplement: Iso-caloric supplement (Control product)
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa

Resource links provided by NLM:

Further study details as provided by Rene Rizzoli, University Hospital, Geneva:

Primary Outcome Measures:
  • Serum insulin like growth factor-1 (IGF-I) level [ Time Frame: 4-week ]
    The main study product effect criterion is the IGF-I level over the 4-week consumption period.

Enrollment: 62
Study Start Date: June 2008
Study Completion Date: April 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral protein supplement (Tested product) Dietary Supplement: Oral protein supplement (Tested product)
Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
Active Comparator: Iso-caloric supplement (Control product) Dietary Supplement: Iso-caloric supplement (Control product)
Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.

Detailed Description:
Study centres: 4 active centres in France and 2 active centres in Switzerland

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women aged between 18 to 40 years (bounds included).
  • Women with a serum IGF-I level below the 25th percentile of the reference value according to the age (bounds included).
  • Women who had given written inform consent.
  • Women with DSM-IV-confirmed anorexia nervosa lasting for at least 6 months. Women with concomitant binge eating and purging type are also included.
  • Women admitted in-hospital for weight and nutritional rehabilitation. It is anticipated that the patient will stay in-hospital during the full duration of the 4-week supplementation phase, and at least 5 weeks within the study.
  • Women being already regular consumers of dairy products.
  • For women with childbearing potential, use of a contraceptive method.
  • Discontinuation of any mineral and vitamin supplements containing calcium and vitamin D, 1 week before starting the product consumption and during the study.

Exclusion Criteria:

  • Women with primary amenorrhea;
  • Women with lactose intolerance;
  • Women with any other metabolic disease that could affect bone metabolism: osteogenesis imperfecta, Paget's disease of bone, hyperthyroidism, primary hyperparathyroidism;
  • Women with current or past neoplasm;
  • Women with any other severe comorbidity;
  • Pregnant or breast feeding women;
  • Women with epilepsy;
  • Women with any current or past use of the following treatments: bisphosphonates, calcitonin, steroids;
  • Patients enrolled in another clinical study within the last 4 weeks;
  • Patients having already received oral nutritional supplements or who need to receive other oral or intravenous (IV) supplements during the follow-up;
  • Patients having received oral or IV nutritional supplements within two weeks before the inclusion;
  • Patients having willed to participate in another clinical study during the present study phase and 4 weeks after the end of their participation in the present study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01823822

Bone Diseases Service, Geneva University Hospitals
Geneva, Switzerland
Sponsors and Collaborators
University Hospital, Geneva
Danone Research
Principal Investigator: René Rizzoli, MD Bone Diseases Service, Department of Internal Medicine Specialties, University Hospitals and Faculty of Medicine of Geneva
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Rene Rizzoli, René Rizzoli, MD (Principal Investigator), University Hospital, Geneva Identifier: NCT01823822     History of Changes
Other Study ID Numbers: 07-182
NU185 ( Other Identifier: Danone Research )
Study First Received: March 29, 2013
Last Updated: April 2, 2013

Keywords provided by Rene Rizzoli, University Hospital, Geneva:
Anorexia nervosa
Protein supplements

Additional relevant MeSH terms:
Anorexia Nervosa
Signs and Symptoms, Digestive
Signs and Symptoms
Feeding and Eating Disorders
Mental Disorders
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017